Therefore the observation that sorafenib may trigger the sensitization of resistant HCC cells to TRAIL-induced apoptosis through STAT3 inhibition [71] or through Mcl-1 downregulation [59], point to this compound as an attractive drug for TRAIL combined therapeutic approaches. This evidence concerns the gene STAT3 and hepatocellular carcinoma.